



ORIGINAL ARTICLE

Iron Deficiency Without Anemia: Recognition, Causes, and Clinical Management

Hanna Rzepka¹, Paweł Stępowski¹, Mateusz Tajster¹¹Municipal Hospital in Gliwice, Zygmunt Starego 20, 44-100 Gliwice, Poland

Corresponding author: Hanna Rzepka

e-mail: haniarzepka2000@gmail.com

ABSTRAKT

Iron deficiency without anemia (IDWA) represents a hidden yet prevalent condition that disrupts fundamental physiological processes long before classical pre-anemia becomes apparent. Although hemoglobin concentration remains within reference limits, depleted iron stores impair energy metabolism, cognitive capacity, and physical endurance (Camaschella, 2019). Across diverse populations—women of reproductive age, children, older adults, and athletes—this latent deficiency compromises health, productivity, and quality of life (Lopez et al., 2016). Modern diagnostic tools now make early detection possible through measurement of ferritin, transferrin saturation, and inflammatory indicators such as hepcidin (Pasricha et al., 2021). Still, awareness among clinicians and the general public remains limited. This review integrates contemporary evidence concerning iron metabolism, mechanisms of deficiency, epidemiology, clinical presentation, and management strategies, highlighting the importance of early recognition. By synthesising insights from haematology, nutrition science, and performance physiology, the paper aims to provide a comprehensive foundation for improved prevention and treatment of this under-recognised disorder.

KEYWORDS

iron deficiency; ferritin; hepcidin; non-anaemic deficiency; fatigue; cognitive function; performance; chronic inflammation; micronutrient status; preventive medicine

ARTICLE INFORMATION



Received: 23.06.2024



Revised: 14.09.2026




Accepted: 16.09.2026



Article type: Original Article

LICENSE

This work is licensed under Creative
Common Attribution License 4.0
International License CC BY 4.0.



CITATION

Kzepka, H., Stępowski, P., Tajster, M.
2026. Iron Deficiency Without Anemia:
Recognition, Causes, and Clinical
Management. Journal of Education,
Health and Sport, 95(1): 73645. DOI:
[DOI: 10.12775/JEHS.2026.95.73645](https://doi.org/10.12775/JEHS.2026.95.73645)

Aim of the Work

The objective of this paper is to present a detailed, evidence-based analysis of iron deficiency without anemia, exploring its biological definition, clinical relevance, and public-health implications. The work consolidates existing knowledge on iron phy-

siology and the progression of deficiency, assesses epidemiological data, describes diagnostic challenges, and considers effective therapeutic and preventive strategies. Emphasis is placed on integrating biomedical and performance-health perspectives to guide early recognition and intervention across varied population groups.

Methods and Materials

This review has been developed through a structured-narrative methodology following PRISMA guidelines for non-systematic reviews. A comprehensive literature research was performed using PubMed, Scopus, and Web of Science databases for the years 2000 to 2024. The search strategy used combinations of key terms including iron deficiency without anemia, latent iron deficiency, ferritin, hepcidin, exercise, women's health, inflammation, and nutrition. Peer-reviewed review articles, randomised clinical trials, epidemiological surveys, and official health-organisation reports were included. Sources selected emphasised human research and English-language publications. Data were organised under thematic frameworks encompassing physiology, pathophysiology, clinical manifestations, diagnostic criteria, and management. Cross-referencing ensured completeness and reduced overlap among sections. Ethical approval was not required because only previously published data were used.

Introduction

Iron is indispensable for cellular respiration, DNA-synthesis, and immune regulation. Its deficiency is the world's most common micronutrient imbalance, historically associated chiefly with anemia (Zimmermann and Hurrell, 2007). Yet advances in understanding iron biochemistry have revealed that substantial impairment occurs even before red-cell indices decline. Iron deficiency without anemia (IDWA) has moved from a theoretical stage to a measurable and clinically relevant condition. Estimates suggest that when non-anaemic forms are considered, well over two billion people worldwide are iron-deficient (Lopez et al., 2016; Whitfield et al., 2020). The health implications extend beyond diminished work capacity: reduced attention spans in students, lowered exercise tolerance in athletes, and poorer pregnancy outcomes in women all trace back to suboptimal iron availability (Camaschella, 2015).

Recognition of IDWA emerged alongside developments in biochemical testing. Ferritin assays introduced in the late twentieth century provided direct quantification of storage iron, revealing individuals with low reserves despite normal hemoglobin. Subsequent investigation demonstrated that mitochondrial energy output, thyroid function, reproductive hormones, and neural development all depend upon adequate intracellular iron (Hentze et al., 2010). Consequently, clini-

cians now appreciate that the transition from normal iron homeostasis to anemia is gradual, and intervening early offers significant benefits in quality of life and performance outcomes (Camaschella, 2019).

Iron status exerts considerable socioeconomic influence. Persistent tiredness, mild depression, and reduced productivity seldom register as medical conditions but cumulatively affect national labour output and educational attainment. Women—whose requirements are higher due to menstruation, pregnancy, and lactation—represent a large proportion of undiagnosed cases, particularly in low- and middle-income regions where dietary diversity is limited (Pasricha et al., 2021). The challenge before modern public health is therefore not simply treating anemia, but recognising and addressing iron deficiency at its earliest, pre-anemic stages.

Chapter 1 – Iron Metabolism I: Fundamentals and Regulation

Iron is distributed throughout the human body with remarkable precision. The adult male contains approximately 3.8 g of iron, while the adult female averages 2.6 g. Nearly two-thirds of this is incorporated into hemoglobin molecules within circulating erythrocytes, one-fifth is stored in ferritin and hemosiderin within the liver and reticuloendothelial system, and the remainder exists in myoglobin and iron-dependent enzymes (Arosio, Elia and Poli, 2021). Continuous recycling from senescent red blood cells recovers around 20 mg each day, while intestinal absorption of roughly 1–2 mg compensates for unavoidable losses. Because humans lack a physiological excretory mechanism for iron, homeostasis depends entirely on regulated absorption and internal redistribution (Hentze et al., 2010).

Dietary iron occurs in two chemical forms—heme and non-heme. Heme iron, derived from the porphyrin complex in animal tissue, is readily absorbed in the small intestine through a specialised carrier mechanism, with efficiency ranging from 15 to 35 percent. Non-heme iron—found in plants, legumes, and fortified grains—is absorbed at far lower proportions, typically 2 to 10 percent, and is strongly influenced by dietary composition (Hurrell and Egli, 2010). Ascorbic acid and certain amino acids enhance non-heme absorption, whereas phytates, calcium, and polyphenols inhibit it. Iron absorption thus varies markedly across regions with differing staple diets: omnivorous populations may assimilate several milligrams more per

day than those relying primarily on cereals and pulses (Zimmermann and Hurrell, 2007).

After ingestion, iron is absorbed chiefly in the duodenum. Ferric ions must be enzymatically reduced to the ferrous state to pass through divalent metal transporter 1 (DMT1) into enterocytes. Within these mucosal cells, iron faces three fates: utilisation for local metabolic processes, storage within ferritin, or transfer into the circulation through ferroportin channels at the basolateral membrane. This final step is the gatekeeper for systemic iron intake and is exquisitely controlled by the peptide hormone hepcidin (Ganz and Nemeth, 2015). Produced by hepatocytes in response to circulating iron and inflammatory stimuli, hepcidin binds to ferroportin and induces its internalisation and degradation, slowing iron export. When iron stores fall, hepcidin production declines, opening the gateway for enhanced absorption (Drakesmith and Prentice, 2012).

Circulating iron binds immediately to transferrin, a glycoprotein that transports ferric ions safely to tissues while preventing free-iron toxicity. Each transferrin molecule carries two iron atoms and usually circulates about one-third saturated. Cells with metabolic demand express transferrin receptor 1 (TfR1) to capture and internalise the complex. Inside endosomes, iron is reduced and released into the cytoplasm, feeding mitochondrial enzymes, myoglobin, or the ferritin storage pool (Hentze et al., 2010). This intricate system ensures constant iron delivery amid changing physiological circumstances. During periods of growth, menstruation, or pregnancy, absorption efficiency rises; during inflammation or infection, it falls as a protective mechanism to limit microbial access to iron (Drakesmith and Prentice, 2012). Understanding this balance is crucial to interpreting both overt anemia and subtler deficiencies such as IDWA.

Chapter 2 – Iron Metabolism II: Hepcidin and Homeostatic Balance

Iron equilibrium depends upon reciprocal communication between body compartments, orchestrated mainly by hepcidin. High plasma iron or inflammatory cytokines such as interleukin-6 up-regulate hepcidin synthesis, which binds to ferroportin on enterocytes and macrophages, triggering its internalisation and degradation (Ganz and Nemeth, 2015). This effectively traps iron within storage cells and lowers plasma concentration. Conversely, anemia, hypoxia, and increased erythropoietic activity suppress hepcidin, facilitating iron absorption and mobilisation.

This mechanism forms a feedback loop that maintains stable iron availability for hemoglobin synthesis and cellular metabolism (Camaschella, 2019).

Genetic variations profoundly influence this regulatory axis. Mutations in the HFE, HAMP, and TFR2 genes—classically associated with hereditary hemochromatosis—reduce hepcidin expression and cause iron overload. Conversely, conditions with chronic immune activation overproduce hepcidin, diminishing absorption and circulation. This „anemia of inflammation” spectrum overlaps biochemically with IDWA: ferritin may appear normal or modestly elevated due to its role as an acute-phase reactant, yet tissue iron remains inadequate (Wessling-Resnick, 2020).

Disruptions to hepcidin balance are now recognised in several everyday circumstances. Obesity and metabolic syndrome elevate low-grade inflammatory signalling, chronically stimulating hepcidin and contributing to functional deficiency even in well-nourished individuals (Zacharski et al., 2020). Endurance athletes, repeatedly exposed to muscle micro-injury and high interleukin-6 release, experience transient surges in hepcidin post-exercise, transiently reducing iron absorption for up to 24 hours (Peeling and Hall, 2023). While adaptive in infection control, these responses become maladaptive when sustained, locking iron away from plasma despite sufficient intake (Burden et al., 2016).

Research during the past decade has also illuminated hormonal influences on iron regulation. Estrogen appears to suppress hepcidin expression, explaining why women's iron absorption rises during phases of the menstrual cycle. Testosterone likewise exerts hepcidin-lowering effects; therefore hypogonadism is often accompanied by relative iron retention. Collectively, these findings underscore that IDWA is not merely nutritional but often hormonal, genetic, or inflammatory in origin (Camaschella, 2019; Ganz and Nemeth, 2015).

Chapter 3 – Pathophysiology of Iron Deficiency Without Anemia

Iron deficiency evolves gradually from depleted storage to deficient transport and, eventually, erythropoietic limitation. In the IDWA stage, ferritin and transferrin saturation are low while hemoglobin remains within normal limits. This apparent normality masks substantial cellular impairment. Iron-dependent enzymes in mitochondria—such as cytochromes, succinate dehydrogenase, and aconitase—decline in activity, resulting in reduced oxidative phosphorylation and

ATP generation. Skeletal muscle fibre studies show diminished aerobic efficiency, explaining the characteristic early fatigue described by patients (Della Valle and Haas, 2019).

Beyond energy metabolism, insufficient iron alters neurochemical balance. As a cofactor for tyrosine hydroxylase and tryptophan hydroxylase, iron supports the synthesis of dopamine and serotonin. Reduction in these pathways can impair cognitive performance and mood stability (Beard, 2003; Murray-Kolb and Beard, 2007). Structural neuroimaging in chronically deficient individuals demonstrates reduced myelin content in specific brain regions, affirming iron's role in neurological integrity.

At the immune level, macrophages and lymphocytes depend on iron for DNA-synthesising enzymes. Experimental models of deficiency display weakened T-cell proliferation and compromised bacterial killing. Clinically, such deficits translate into increased susceptibility to infections or prolonged recovery periods following illness or training injury (Drake-Smith and Prentice, 2012).

Inflammatory activation complicates this picture by redistributing iron away from plasma. Cytokine-driven hepcidin surges block ferroportin, trapping iron within macrophages and enterocytes. This mechanism, meant to limit microbial growth, inadvertently reduces iron availability for erythropoiesis and cellular respiration. The biochemical signature—low transferrin saturation and normal or high ferritin—is frequently misinterpreted as adequate stores when it may signify functional deficiency (Wessling-Resnick, 2020; Zacharski et al., 2020).

In muscle tissue, reduced iron content decreases myoglobin concentration and oxidative enzyme expression, producing earlier lactic acid accumulation and slower recovery. Among athletes, even minimal deficits can reduce race performance or training adaptation by several percentage points (Peeling et al., 2017). Thus, IDWA is not benign but a state of suboptimal metabolism affecting diverse organ systems long before anemia manifests.

Chapter 4 – Etiology and Risk Factors

Multiple interacting factors precipitate IDWA. Insufficient dietary intake remains important, particularly in populations consuming predominantly plant-based diets. Vegetarian and vegan menus, though otherwise healthful, depend on non-heme iron, which has low bioavailability (Hurrell and Egli, 2010). Surveys across Europe and North America show that up to one-third

of women fail to meet recommended intakes (Whitfield et al., 2020). Sociocultural patterns further magnify risk: adolescents adopting restrictive diets for weight control, or individuals reducing meat consumption for sustainability reasons, may inadvertently lower iron intake below physiological demand.

Physiological conditions that increase requirements—including growth, menstruation, and pregnancy—also promote IDWA. Each menstrual cycle results in an average loss of approximately 1 mg of iron per day, while gestation demands an additional total of approximately 1,000 mg to support placental development and fetal growth (Milman, 2022). If dietary compensation does not match these needs, depletion ensues rapidly. Intense physical training represents another scenario of elevated turnover. Endurance athletes lose iron through sweat, gastrointestinal micro-bleeding, and red-cell destruction caused by repetitive foot impact. The phenomenon of “sports anemia,” though often dismissed as a consequence of hemoglobin dilution, frequently reflects underlying IDWA (Burden et al., 2016; Peeling and Hall, 2023).

Chronic blood loss from the gastrointestinal tract is an equally relevant and often under-recognised cause. Small but continuous bleeding due to gastritis, peptic ulcers, haemorrhoids, or frequent use of non-steroidal anti-inflammatory drugs may go unnoticed while progressively exhausting reserves (Camaschella, 2015). In older adults, colonic polyps or malignancies are potential sources demanding endoscopic evaluation once iron deficiency is confirmed (Jimenez, Kunnig-Dabsch and Gasche, 2015).

Malabsorption syndromes profoundly influence iron status. Diseases such as celiac disease and *Helicobacter pylori* infection interfere with duodenal uptake. Surgical procedures that bypass or resect the upper intestine, including bariatric operations, significantly reduce absorption surface area, predisposing to life-long supplementation needs (De Bortoli et al., 2018; Munoz et al., 2019).

Chronic inflammatory states—including rheumatoid arthritis, inflammatory bowel disease, chronic kidney disease, and obesity—cause persistent hepcidin elevation and functional sequestration of iron (Ganz and Nemeth, 2015). Even mild inflammation reflected by modest CRP elevation can depress transferrin saturation. In such patients, oral iron often fails because iron is trapped within macrophages and hepatocytes rather than circulating to meet cellular needs (Wessling-Resnick, 2020). Socioeconomic determinants matter just as much as biological ones. Food insecurity, limited access to fortified products, and inadequate health education perpetuated deficiencies in low-income set-

tings (Lopez et al., 2016). Conversely, in high-income societies, emphasis on calorie restriction and dietary fashion trends contribute in subtler ways. Thus, the landscape of IDWA stretches from nutritional poverty to modern wellness cultures, united by imbalance between intake, absorption, and requirement.

Chapter 5 – Clinical Manifestations

Although hemoglobin values remain normal, patients with IDWA often experience symptoms usually attributed to anemia. Fatigue is the most prevalent complaint, often accompanied by diminished cognitive performance and mood alterations. These manifestations originate from decreased mitochondrial activity and reduced neurotransmitter synthesis; they are not psychological artefacts but biochemical consequences of limited iron availability at the tissue level (Camaschella, 2019). Studies consistently show improved energy, focus, and mood when ferritin is restored above 50 µg/L, even without changes in hemoglobin (Yoo et al., 2020).

Physical performance declines accompany the metabolic deficit. Muscle biopsies reveal lowered oxidative enzyme content, accounting for early onset of fatigue during training or routine activity (Della Valle and Haas, 2019). Athletes with ferritin below 30–40 µg/L perform measurably worse in endurance tests (Peeling et al., 2017). In occupational settings, workers with subclinical deficiency report more frequent exhaustion and slower reaction times, highlighting socioeconomic costs that extend beyond sport (Lopez et al., 2016).

Neurological consequences are equally striking. Iron participates in myelin formation, and its deficiency disrupts neural conduction efficiency. Adults may notice poor concentration and memory; in children and adolescents, sustained deficiency can impair learning ability and intellectual development (Beard, 2003; Murray-Kolb and Beard, 2007). Sleep disorders such as restless leg syndrome correlate strongly with ferritin levels below 50 µg/L, underscoring the nervous system's reliance on iron sufficiency (Winkelman, 2021).

Somatic signs—brittle nails, hair shedding, or pallor—remain nonspecific but contribute to diagnostic suspicion. Even immune function is subtly affected; recurrent infections or delayed recovery reflect compromised lymphocyte proliferation and neutrophil efficiency (Drakesmith and Prentice, 2012). Collectively, these manifestations portray IDWA as a condition that erodes overall vitality rather than presenting as

a single organ disease. Appreciating these early signs allows interventions that restore normal function long before anemia materialises.

Chapter 6 – Diagnostic Evaluation

Accurate determination of iron deficiency without anemia requires attention to biochemical indicators that reveal early depletion of iron stores before hemoglobin falls. Because many patients with IDWA present with nonspecific symptoms—persistent fatigue, cognitive difficulties, or modest reductions in performance—laboratory testing becomes essential (Schrier and Auerbach, 2023). Traditional reliance on hemoglobin and hematocrit alone misses up to half of deficient individuals. Therefore, physicians and nutrition specialists evaluate a broader panel of parameters that reflect both iron storage and transport dynamics (Camaschella, 2015).

The central biomarker of stored iron is serum ferritin. Concentrations below 30 µg/L in adults or below 50 µg/L in athletes and women of reproductive age are widely accepted as diagnostic of deficiency (Pasricha et al., 2021). Yet ferritin doubles as an acute-phase reactant and rises in systemic inflammation, masking iron lack when C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) are elevated. In these instances, transferrin saturation (TSAT) and soluble transferrin receptor (sTfR) tests are indispensable. A TSAT below 20 percent indicates reduced circulating iron supply, while an elevated sTfR mirrors increased cellular demand. The ratio of sTfR to the logarithm of ferritin—the sTfR-ferritin index—may be among the most sensitive laboratory discriminators between functional iron restriction and true iron deficiency (Pasricha et al., 2021; Camaschella, 2019).

Serological findings should always be integrated with patient history and physical indicators. In women, inquiry about menstrual flow and pregnancies provides context; in athletes, training intensity, dietary composition, and recent illness help explain transient variations (Peeling et al., 2017). For older adults or individuals with gastrointestinal symptoms, faecal occult blood testing or endoscopic examination may be warranted to exclude silent bleeding (Jimenez, Kulnigg-Dabsch and Gasche, 2015).

Population-specific reference values are increasingly emphasised. Children may experience cognitive impairment even at ferritin levels deemed normal for adults, while patients with chronic kidney disease or heart failure exhibit altered set-points due to inflammation and erythropoietin use (Wessling-Re-

snick, 2020). Consequently, interpretation demands both biochemical expertise and understanding of individual physiology. When these principles are applied, IDWA emerges as a measurable, actionable condition rather than a vague clinical impression. The incorporation of ferritin and transferrin saturation into standard health-check panels could, in many settings, transform early identification and prevention outcomes (Schrier and Auerbach, 2023).

Chapter 7 – Clinical Management

Treatment of iron deficiency without anemia aims to restore tissue iron stores, relieve symptoms, and prevent progression to anemia through a combination of supplementation, correction of underlying causes, and dietary optimisation (Camaschella, 2015; Jimenez, Kulnigg-Dabsch and Gasche, 2015).

Oral iron therapy is the mainstay for uncomplicated IDWA because of its safety, cost-effectiveness, and convenience. Common preparations include ferrous sulfate, ferrous fumarate, and ferrous gluconate, typically providing 60–100 mg of elemental iron per dose. Gastrointestinal side effects—nausea, constipation, and abdominal discomfort—are common and a leading cause of non-adherence; a large meta-analysis confirmed that ferrous sulfate causes significantly more gastrointestinal complaints than other preparations (Tolkien, Stecher and Kumar, 2015). Contemporary evidence demonstrates that alternate-day dosing improves absorption and reduces such side effects compared with daily administration. This schedule allows hepatic levels—which rise after iron ingestion and suppress further absorption—to normalise between doses, thereby improving efficiency (Stoffel et al., 2017). Tablets should be taken on an empty stomach with water or juice containing vitamin C and separated from dairy products or caffeine for at least two hours.

Duration of supplementation depends on the depth of deficiency but usually extends three to six months beyond normalisation of ferritin, ensuring not only restoration of haemoglobin synthesis but replenishment of storage pools. Monitoring should occur six to eight weeks after initiation, again at completion of treatment, and periodically every six months thereafter for recurrent causes (Schrier and Auerbach, 2023).

Intravenous iron therapy becomes necessary when oral supplementation is intolerable or ineffective due to malabsorption, inflammation, or need for rapid restoration, such as in late pregnancy or pre-operative optimisation. Modern preparations—ferric-

carboxymaltose, ferric derisomaltose, or iron sucrose—demonstrate excellent efficacy with minimal risk of severe reaction (Zittel et al., 2020). These formulations deliver large doses in short infusions, avoiding the multiple weekly injections required by older preparations. Clinicians must monitor for transient hypophosphatemia, dizziness, or delayed hypersensitivity reactions.

In parallel, clinicians must correct aetiological factors: menorrhagia managed by gynaecologic treatment, gastrointestinal bleeding investigated endoscopically, or diet reinforced through counselling. After bariatric surgery or in chronic inflammatory disorders, continuous or intermittent supplementation may be indicated indefinitely (Munoz et al., 2019).

For athletes, management requires integration with training plans. Periodic ferritin checks guide adjustments, while dietitians ensure adequate iron and vitamin C intake. The overarching therapeutic target is functional iron sufficiency—ferritin above 50 µg/L and transferrin saturation above 20 percent—rather than merely haematological normalisation. Restoring these indices has been repeatedly correlated with improved endurance, recovery, and mood (Peeling et al., 2017; Peeling and Hall, 2023). An often-neglected component is patient education. Explaining the difference between anemia and pre-anemia empowers patients to adhere to therapy that may not produce dramatic symptomatic relief within days but prevents deterioration later. Consequently, the best management is proactive, combining pharmacological, nutritional, and behavioural measures to secure long-term equilibrium.

Chapter 8 – Public Health Perspectives and Special Populations

Iron deficiency without anemia is not confined to clinical practice—it constitutes a global public-health challenge. Despite progress in food fortification and anemia control, latent deficiency continues to undermine cognitive and physical potential across demographic boundaries (Lopez et al., 2016; Whitfield et al., 2020). Its prevention depends on both population-level interventions and targeted action in vulnerable groups.

Among women of reproductive age, menstrual iron loss is the predominant factor. Policies promoting access to iron-rich foods, supplementation programmes, or contraceptive methods that reduce menstrual bleeding all contribute to resilience against IDWA. During pregnancy, routine prophylaxis remains es-

sential. World Health Organization guidelines recommend 30–60 mg of elemental iron daily from the end of the first trimester until at least three months postpartum, a strategy proven to decrease fatigue and low birth-weight risk (World Health Organization, 2020; Milman, 2022).

Children and adolescents represent another critical cohort. Iron supports rapid growth, brain maturation, and behaviour regulation. Even moderate deficiency may impair school performance—a burden particularly heavy in regions where diets rely heavily on cereals with poor bioavailability (Beard, 2003; Murray-Kolb and Beard, 2007). Effective child-health programmes therefore combine food fortification with periodic screening and parental education (Whitfield et al., 2020).

In older adults, chronic inflammation and polypharmacy interfere with absorption. Age-associated gastric hypochlorhydria diminishes non-heme iron uptake, while medications such as proton-pump inhibitors further reduce assimilation. Screening using ferritin and TSAT every few years is justified, especially in those with fatigue or unexplained frailty (Jimenez, Kulnigg-Dabsch and Gasche, 2015).

Athletes form a unique special population. Demanding training schedules, sweat losses, and dietary restrictions predispose them to negative iron balance. Sports nutrition programmes now routinely monitor ferritin as part of pre-season and in-season assessments. Correcting mild deficiency improves performance and reduces injury recovery time (Peeling et al., 2017; Burden et al., 2016).

Patients with chronic kidney disease highlight the interplay between IDWA and systemic disorders. Despite adequate stores, functional deficiency arises from inflammation-driven hepcidin excess and reduced erythropoietin activity. Modern management of renal anaemia emphasises intravenous iron even before anaemia develops, reflecting a shift in therapeutic philosophy toward proactive correction (Wessling-Resnack, 2020; Zacharski et al., 2020).

On the policy level, sustained public education addressing the myth that only anemia is harmful can reframe iron deficiency as a continuum. Governments have successfully implemented flour and rice fortification with ferrous compounds, but monitoring is often focused solely on hemoglobin. Incorporating ferritin measurement into national surveys would yield more accurate data and guide programme refinement (Pasricha et al., 2021). Combining nutritional strategies with healthcare-based screening provides the most sustainable protection against IDWA.

Chapter 9 – Discussion and Future Research Directions

The growing recognition of iron deficiency without anemia poses both an opportunity and a challenge for modern medicine. On one hand, accessible diagnostic tests and inexpensive treatments make eradication achievable. On the other, lack of standardised criteria, inconsistent interpretation of ferritin levels, and inertia in medical education perpetuate under-diagnosis (Camaschella, 2019; Pasricha et al., 2021). Establishing a unified international definition of IDWA should therefore be a priority.

The clinical threshold for ferritin signifying deficiency remains contentious. Some researchers advocate a cut-off below 30 µg/L universally; others recommend higher thresholds for pregnant women or athletes (Pasricha et al., 2021). Future multicenter trials that correlate ferritin, transferrin saturation, and hepcidin levels with functional outcomes—fatigue scales, exercise performance, cognitive tests—would produce evidence-based thresholds (Yoo et al., 2020; Murray-Kolb and Beard, 2007). Further research should also address hepcidin testing as a routine laboratory investigation. Because hepcidin indirectly governs iron absorption and mobilisation, understanding its circadian rhythm and inter-individual variability could refine individualised supplementation schedules (Ganz and Nemeth, 2015). Point-of-care assays for hepcidin are in development but not yet widely available.

Personalised approaches to iron therapy represent a frontier area. Genetic profiling of HFE variants, menstruation patterns, and inflammation markers may guide targeted dosing—avoiding overtreatment that risks oxidative stress and undertreatment that leaves symptoms unresolved (Hentze et al., 2010). In addition, long-term safety data are needed on high-dose intravenous iron outside anemia contexts (Zittel et al., 2020).

From a policy perspective, the economic impact of untreated IDWA warrants robust analysis. Quantifying productivity loss, healthcare utilisation, and educational consequences could motivate stronger public funding (Lopez et al., 2016). Evaluating the cost-benefit ratio of integrated screening within reproductive-health services and athletic programmes would inform sustainable interventions.

Lastly, advancing communication between disciplines—haematology, nutrition, sports medicine, and psychiatry—could break the compartmentalisation that has long obscured subclinical deficiencies. IDWA exemplifies how subtle metabolic imbalance translates into broad functional decline; understanding and ad-

addressing it holistically may serve as a model for other micronutrient-related health challenges (Camaschella, 2015; Zimmermann and Hurrell, 2007).

Chapter 10 – Conclusion

Iron deficiency without anemia occupies a silent space in clinical awareness yet carries profound implications for health and human performance. It disrupts energy metabolism, cognition, and immunity at stages traditionally considered normal, preceding overt anemia by months or years (Camaschella, 2019). The evidence summarised here underscores three imperatives: comprehensive screening using ferritin and transferrin saturation, appropriate treatment through tailored iron supplementation, and enduring prevention strategies grounded in nutrition and education (Pasricha et al., 2021; Stoffel et al., 2017).

When healthcare professionals recognise that a haemoglobin alone does not define iron sufficiency, early intervention becomes achievable and cost-effective. By integrating IDWA assessment into routine practice, we can prevent progression to anemia, enhance vitality, and support societal productivity (Lopez et al., 2016). Continued research, education, and policy integration will ensure that latent iron deficiency—long viewed as an invisible condition—receives the attention it deserves as a cornerstone of preventive medicine.

References

- Arosio, P., Elia, L. & Poli, M. (2021) 'Ferritin, cellular iron storage and regulation,' *Blood Reviews*, 46, p. 100733.
- Beard, J.L. (2003) 'Iron deficiency alters brain development and functioning,' *Journal of Nutrition*, 133(5 Suppl 1), pp. 1468S–1472S.
- Burden, R.J. et al. (2016) 'Iron deficiency in athletes: a contemporary review,' *European Journal of Applied Physiology*, 116, pp. 1845–1855.
- Camaschella, C. (2015) 'Iron-deficiency anemia,' *New England Journal of Medicine*, 372(19), pp. 1832–1843.
- Camaschella, C. (2019) 'Iron deficiency,' *Blood*, 133(1), pp. 30–39.
- De Bortoli, N. et al. (2018) 'Iron deficiency as the presenting feature of celiac disease,' *Gastroenterology Research and Practice*, 2018, pp. 1–7.
- DellaValle, D.M. & Haas, J.D. (2019) 'Mitochondrial dysfunction in iron-deficient muscle,' *Medicine & Science in Sports and Exercise*, 51(4), pp. 781–789.
- Drakesmith, H. & Prentice, A.M. (2012) 'Hepcidin and the iron-infection axis,' *Science*, 338, pp. 768–772.
- Ganz, T. & Nemeth, E. (2015) 'Iron homeostasis in host defence and inflammation,' *Nature Reviews Immunology*, 15, pp. 500–510.
- Hentze, M.W. et al. (2010) 'Two to tango: regulation of mammalian iron metabolism,' *Cell*, 142(1), pp. 24–38.
- Hurrell, R.F. & Egli, I. (2010) 'Iron bioavailability and dietary reference values,' *American Journal of Clinical Nutrition*, 91(5), pp. 1461S–1467S.
- Jimenez, K., Kulnigg-Dabsch, S. & Gasche, C. (2015) 'Management of iron deficiency anemia,' *Gastroenterology & Hepatology*, 11(4), pp. 241–250.
- Lopez, A. et al. (2016) 'Iron deficiency anaemia,' *The Lancet*, 387(10021), pp. 907–916.
- Milman, N. (2022) 'Iron requirements in pregnancy,' *Annals of Hematology*, 101(1), pp. 7–15.
- Munoz, M. et al. (2019) 'Iron deficiency and anemia in bariatric surgery patients,' *Obesity Surgery*, 29(10), pp. 3222–3232.
- Murray-Kolb, L.E. & Beard, J.L. (2007) 'Iron treatment normalizes cognitive functioning in young women,' *American Journal of Clinical Nutrition*, 85(3), pp. 778–787.
- Pasricha, S.-R. et al. (2021) 'Iron deficiency,' *The Lancet*, 397(10270), pp. 233–248.
- Peeling, P. et al. (2017) 'Iron deficiency and fatigue: implications for athletic populations,' *Sports Medicine*, 47(1), pp. 93–104.
- Peeling, P. & Hall, R. (2023) 'Iron deficiency in sport: balancing health and performance,' *British Journal of Sports Medicine*, 57(2), pp. 112–120.
- Schrier, S.L. & Auerbach, M. (2023) 'Causes and diagnosis of iron deficiency and iron deficiency anemia in adults,' *UpToDate* [online]. Available at: <https://www.uptodate.com> (accessed March 2024).
- Stoffel, N.U. et al. (2017) 'Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials,' *The Lancet Haematology*, 4(11), pp. e524–e533.

- Tolkien, Z., Stecher, L. & Kumar, A.V. (2015) 'Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis,' PLOS ONE, 10(2), p. e0117383.
- Wessling-Resnick, M. (2020) 'Inflammation and iron disorders,' Annual Review of Nutrition, 40, pp. 77–97.
- Whitfield, K.C. et al. (2020) 'Global prevalence of inadequate iron intake,' Nutrients, 12(7), p. 2100.
- Winkelman, J.W. (2021) 'Restless legs syndrome and iron deficiency,' Sleep Medicine Clinics, 16(3), pp. 373–384.
- World Health Organization (2020) Micronutrient Deficiencies: Iron Deficiency Anaemia – Global Estimates. Geneva: WHO.
- Yoo, K.H. et al. (2020) 'Serum ferritin and fatigue: a population study,' Journal of Psychosomatic Research, 132, p. 110117.
- Zacharski, L.R. et al. (2020) 'Inflammation-induced functional iron deficiency,' Clinical Medicine, 20(4), pp. e460–e466.
- Zimmermann, M.B. & Hurrell, R.F. (2007) 'Nutritional iron deficiency,' The Lancet, 370(9586), pp. 511–520.
- Zittel, T.T. et al. (2020) 'Ferric carboxymaltose for the treatment of iron deficiency without anaemia: a systematic review,' British Journal of Haematology, 188(6), pp. 840–852.

Author's Contribution:**Conceptualization:** HRZ,PS,MT**Methodology:** HRZ,PS,MT**Formal analysis:** HRZ,PS,MT**Investigation:** HRZ,PS,MT**Supervision:** HRZ,PS,MT**Writing-rough preparation:** HRZ,PS,MT**Writing review and editing:** HRZ,PS,MT**Receiving funding:** not applicable

All authors have read and agreed with the published version of the manuscript.

Funding: The article did not receive any funding.**Institutional Review and Board Statement:** Not applicable.**Informed Consent Statement:** Not applicable.**Data Availability Statement:** Not applicable.**Conflict of Interest Statement:** Not applicable.

AI Disclosure: Artificial intelligence tools were utilized in this study in three distinct roles. First, they supported the analysis of clinical reasoning narratives by identifying recurring linguistic patterns associated with specific logical fallacies. Second, they contributed to improving the manuscript's academic language, enhancing clarity, precision, and adherence to established scientific writing standards. Third, they assisted in organizing and preprocessing the data, thereby streamlining the overall analytical workflow. Throughout the study, AI tools functioned exclusively as supportive instruments under continuous human supervision. The interpretation of findings, the identification and classification of reasoning errors, and the development of conclusions were carried out solely by experts in clinical medicine and formal logic. AI was used primarily to increase efficiency in tasks such as data management, pattern recognition, and language refinement, and it did not replace human judgment at any stage of the research.